Evidence map›Paper›PMID 31115842›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2019

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Henning Andersen, Renato Mantegazza, Jing Jing Wang, Fanny O'Brien, Kaushik Patra, James F Howard, REGAIN Study Group

Registry-linked trialOpen access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02301624 (A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02301624 phase3completednot on this map

A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

TypeinterventionalSponsorAlexion Pharmaceuticals, Inc.Ran2014 to 2019Enrolled117ConditionsRefractory Generalized Myasthenia GravisArmsEculizumab, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Henning AndersenDepartment of Neurology, Aarhus University Hospital, Indgang J, Plan 5, Krydspunkt 504, Palle Juul-Jensens Boulevard, 8200, Aarhus N, Denmark. hennande@rm.dk.ORCID http://orcid.org/0000-0002-9082-2694
Renato MantegazzaFoundation of the Carlo Besta Neurological Institute, IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-9810-5737
Jing Jing WangFormerly of Alexion Pharmaceuticals, Inc., New Haven, CT, USA.
Fanny O'BrienAlexion Pharmaceuticals, Inc., New Haven, CT, USA.
Kaushik PatraAlexion Pharmaceuticals, Inc., New Haven, CT, USA.
James F HowardDepartment of Neurology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-7136-8617
REGAIN Study Group
Alexion Pharmaceuticals (United States) · USAarhus University Hospital · DKUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article "Eculizumab improves fatigue in refractory generalized myasthenia gravis", written by "Henning Andersen, Renato Mantegazza, Jing Jing Wang, Fanny O'Brien, Kaushik Patra, James F. Howard Jr. and The REGAIN Study Group" was originally published electronically on the publisher's internet portal (currently SpringerLink) on 23 March 2019 without open access.

Identifiers

PMID31115842
PMCPMC6620249
OpenAlexW2945476297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.